AstraZeneca’s Fasenra, an IL-5-targeting monoclonal antibody already approved for asthma, represents a promising contender ...
Guggenheim adjusted its price target on shares of AstraZeneca (NASDAQ:AZN:LN) (NASDAQ: AZN), increasing it to GBP13,100 from ...
From accelerating drug development and clinical trials to supercharging collaboration, machine learning-enhanced healthcare ...
AstraZeneca restructures its China operations following leadership scandals and sales challenges, appointing new executives ...
Amgen’s Lumakras and AstraZeneca’s Calquence are both in line to expand their respective oncology reaches with new FDA ...
Guggenheim raised the firm’s price target on AstraZeneca (AZN) to 13,100 GBp from 12,600 GBp and keeps a Buy rating on the shares. The firm is ...
Mina Makar highlights AstraZeneca's commitment to advancing heart failure research and innovative therapies, addressing ...
AstraZeneca PLC AZN shares inched up 0.87% to £109.38 Friday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100 Index UKX rising 1.35% to 8,505.22.
It’s a sobering statistic: 1 in 8 women in the United States will be diagnosed with breast cancer during her lifetime.1 ...